ReviewJournal of clinical microbiology2020
Advances in Molecular Diagnosis of Tuberculosis.
Review in Journal of clinical microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 110 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
110 citing papers in PubMed, 1 synthesis or guideline pooled it, 199 citations in OpenAlex.
- Meta-analysis of diagnostic accuracy of nucleic acid amplification tests for abdominal tuberculosis.PloS one · 2023Pooled it
- Rapid drug resistance prediction in positiveEmerging microbes & infections · 2026Article
- Review
- Diagnostic accuracy of GeneReady MTB assay on sputum for detecting pulmonary tuberculosis: a prospective multicenter study in China.Journal of clinical microbiology · 2026Article
- Article
- A multi-center clinical evaluation on first-in-class ROP-based IGRA for tuberculosis diagnosis.iScience · 2026Article
- Multidrug-resistant tuberculosis (MDR-TB) in people living with HIV: Clinical issues, therapeutic challenges and perspectives in sub-Saharan Africa. A narrative review.Journal of clinical tuberculosis and other mycobacterial diseases · 2026Review
- Key impact of Beijing strains including new resistant clusters on spread of multidrug-resistant tuberculosis in northern Russia.Microbiology spectrum · 2026Article
- The Impact of Adopting Whole-Genome Sequencing for Tuberculosis Diagnosis in China: A Cost-Effectiveness Analysis.Open forum infectious diseases · 2026Article
- Tuberculosis Diagnostic Methods: Clinical Applicability, Implementation Challenges, and Integrated Testing Strategies.Pathogens (Basel, Switzerland) · 2026Review
- Optimizing pathological diagnosis of tuberculosis: qPCR outperforms acid-fast staining in formalin-fixed paraffin-embedded tissues and enables resistance profiling.Frontiers in medicine · 2026Article
- Real-world performance of iFIND-TBR for rapid detection ofFrontiers in microbiology · 2026Article
- Integrative transcriptomic meta-analysis reveals conserved transcriptional signatures and predictive biomarkers for active tuberculosis: a pathway-based machine learning approach.Frontiers in microbiology · 2026Article
- A Systematic Review and Meta-analysis on Innovative Approaches in Tuberculosis Diagnosis: Challenges and Future Directions.International journal of MCH and AIDS · 2026Review
- Multiscale geographically weighted modeling of tuberculosis incidence in China: integrating geographic perspectives into epidemiological analysis.International journal of health geographics · 2025Article
- Transforming tuberculosis diagnosis with clinical metagenomics: progress and roadblocks.Journal of clinical microbiology · 2025Review
- Detection of rifampin-resistant Mycobacterium tuberculosis using CRISPR/Cas14a-enabled molecular techniques.BMC infectious diseases · 2025Article
- TOAST: a novel tool for designing targeted gene amplicons and an optimised set of primers for high-throughput sequencing in tuberculosis genomic studies.BMC genomics · 2025Article
- Off-label evaluation of the BD MAX MDR-TB assay for rapid diagnosis of rifampicin and isoniazid resistance ofJournal of clinical microbiology · 2025Article
- Discrepancies in isoniazid susceptibility profiles: Bactec MGIT 960-resistant but GenoType MTBDRMicrobiology spectrum · 2025Article
50 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 4 countries.
Funding
Abstract
Molecular tests for tuberculosis (TB) have the potential to help reach the three million people with TB who are undiagnosed or not reported each year and to improve the quality of care TB patients receive by providing accurate, quick results, including rapid drug-susceptibility testing. The World Health Organization (WHO) has recommended the use of molecular nucleic acid amplification tests (NAATs) tests for TB detection instead of smear microscopy, as they are able to detect TB more accurately, particularly in patients with paucibacillary disease and in people living with HIV. Importantly, some of these WHO-endorsed tests can detect mycobacterial gene mutations associated with anti-TB drug resistance, allowing clinicians to tailor effective TB treatment. Currently, a wide array of molecular tests for TB detection is being developed and evaluated, and while some tests are intended for reference laboratory use, others are being aimed at the point-of-care and peripheral health care settings. Notably, there is an emergence of molecular tests designed, manufactured, and rolled out in countries with high TB burden, of which some are explicitly aimed for near-patient placement. These developments should increase access to molecular TB testing for larger patient populations. With respect to drug susceptibility testing, NAATs and next-generation sequencing can provide results substantially faster than traditional phenotypic culture. Here, we review recent advances and developments in molecular tests for detecting TB as well as anti-TB drug resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.